358 related articles for article (PubMed ID: 33464409)
1. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
2. The role of ASCT2 in cancer: A review.
Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L
Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
4. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
5. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
6. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
7. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
8. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
9. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
[TBL] [Abstract][Full Text] [Related]
10. Establishment of monoclonal antibodies against cell surface domains of ASCT2/SLC1A5 and their inhibition of glutamine-dependent tumor cell growth.
Suzuki M; Toki H; Furuya A; Ando H
Biochem Biophys Res Commun; 2017 Jan; 482(4):651-657. PubMed ID: 27865832
[TBL] [Abstract][Full Text] [Related]
11. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
12. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.
Gegelashvili M; Rodriguez-Kern A; Pirozhkova I; Zhang J; Sung L; Gegelashvili G
Neurochem Int; 2006; 48(6-7):611-5. PubMed ID: 16516348
[TBL] [Abstract][Full Text] [Related]
13. The pro-proliferative effect of interferon-γ in breast cancer cell lines is dependent on stimulation of ASCT2-mediated glutamine cellular uptake.
Silva C; Andrade N; Rodrigues I; Ferreira AC; Soares ML; Martel F
Life Sci; 2021 Dec; 286():120054. PubMed ID: 34662550
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
15. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
16. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
17. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.
Schulte ML; Fu A; Zhao P; Li J; Geng L; Smith ST; Kondo J; Coffey RJ; Johnson MO; Rathmell JC; Sharick JT; Skala MC; Smith JA; Berlin J; Washington MK; Nickels ML; Manning HC
Nat Med; 2018 Feb; 24(2):194-202. PubMed ID: 29334372
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
20. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]